@celularity profile picture
Celularity Inc. (NASDAQ:CELU) @celularity

A next-generation Biotechnology company creating off-the-shelf cellular medicines for Cancer, Infectious Diseases, and Degenerative Diseases. (NASDAQ:CELU)

Joined August 2016
  • Tweets 281
  • Following 259
  • Followers 7,183
Photos and videos
RELEASE: Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law Read the full release here: globenewswire.com/news-relea…
1
1
2
104
RELEASE: Celularity secures strategic license deal worth up to $35M, strengthening capital position while focusing on longevity therapeutics. Read the full release here: globenewswire.com/news-relea…
1
2
267
RELEASE: Celularity Inc. (Nasdaq: CELU) Receives $12.2 Million from Sale of New Jersey Net Operating Losses Read the full release here: globenewswire.com/news-relea…
1
2
284
RELEASE: Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations Dr. Robert J. Hariri welcomed the recent action taken under the leadership of CMS Administrator Dr. Mehmet Oz. globenewswire.com/news-relea…
4
5
442
RELEASE: Celularity announces the closing of its previously disclosed financing transactions with Philip A. Barach, co-founder and former president of DoubleLine Capital LP. globenewswire.com/news-relea…

Celularity Announces Closing of Financing Transactions

FLORHAM PARK, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company...

globenewswire.com
2
189
RELEASE: Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision READ THE FULL RELEASE HERE: globenewswire.com/news-relea…
146
Big announcement! We are excited to be part of DefEYE’s focused expansion into the ophthalmic space and to demonstrate the transformative power of placental-derived regenerative biologic solutions. Read the full release here: globenewswire.com/news-relea…
5
8
628
Exciting news! Celularity Phase 2 clinical trial results published on the safety and efficacy of placenta-derived cells for diabetic foot ulcers complicated by Peripheral Artery Disease. Read the full release here: globenewswire.com/news-relea…

Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the...

First-in-class regenerative therapy for diabetic foot ulcers complicated by peripheral artery diseaseCelularity PDA-002 achieved durable wound healing with...

globenewswire.com
1
2
6
615
We are pleased to report that we have filed our Form 10-Q quarterly reports for the first and the second quarters 2025. This comes on the heels of the recently announced retirement of all $32.0 million senior secured debt. Read the full release here: globenewswire.com/news-relea…

Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second...

Company on Friday, August 29, 2025, filed quarterly reports on Form 10-Q for the periods ended March 31, 2025, and June 30, 2025, respectively, in accord...

globenewswire.com
1
2
5
559
We have successfully monetized Celularity’s intellectual property assets to retire the Company’s senior secured debt in its entirety while retaining exclusive use of the assets for our cell therapy, advanced biomaterials, and biobanking businesses. globenewswire.com/news-relea…
1
5
14
1,008
RELEASE: Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law Read it here: globenewswire.com/news-relea…
1
7
15
1,133
Release: Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies globenewswire.com/news-relea…
2
2
11
1,091
Advancing Ocular Surface Reconstruction: Our DDHAM-3L technology, with its unique biological properties, offers a promising platform for delivering patient-specific, iPSC-derived LSCs to restore vision and improve patient outcomes. globenewswire.com/news-relea…

Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic...

Highlights the unique potential of Celularity’s proprietary advanced biomaterial technology as a novel cellular delivery system for ocular surface...

globenewswire.com
1
3
6
660
Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products Read the full release here: globenewswire.com/news-relea…
1
4
9
851
An important publication form our team in Frontiers in Immunology: Senescence, NK Cells, and Cancer. Read the full release - with link to the publication - here: globenewswire.com/news-relea…
1
4
588
Excited to receive FDA Tissue Reference Group recommendation letters on the newest additions to our portfolio of human placental-derived biomaterials. Full story here: globenewswire.com/news-relea…
1
5
611
We are delighted to announce a strategic collaboration with BlueSphere Bio, Inc., which will bring together our core strengths in cell manufacturing, process development and BSB’s development of novel cell therapies to treat high risk leukemias. globenewswire.com/news-relea…
1
5
619
Celularity Founder and CEO Dr. Robert Hariri to be a Keynote Speaker at the Longevity Med Summit this May, discussing cellular therapies for human performance and longevity. #longevity #stemcells lifespan.io/news/the-3rd-lon…
2
13
666
A great feature in Drug Target Review's Beyond the Lab Report on the work Celularity is doing in the realm of stem cell therapies. (Found on page 6.) indd.adobe.com/view/d551a70e…
2
10
1,108
Celularity, Inc. is proud to be a member of the MASS Coalition, a group of business leaders who together are working with the new administration to prevent amputation and other complications associated with Diabetes and Cardiovascular disease.  saveourwoundcare.org/media/
1
2
7
864
Load more